MEN1-Related Neuroendocrine Tumors Show c-MET Overexpression

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Multiple endocrine neoplasia type 1 (MEN1) patients have high mortality from duodenopancreatic neuroendocrine tumors (NETs).
• Current treatments combining c-MET inhibitors and anti-VEGF show promise for sporadic NETs, but efficacy in MEN1-NETs is unknown.

Purpose of the Study:

• To characterize c-MET expression in MEN1-related NETs.
• To evaluate the association between c-MET expression and clinicopathologic features in MEN1-NETs.

Main Methods:

• Analysis of 43 tumors from 22 genetically confirmed MEN1 patients with metastatic NETs.
• Immunohistochemistry used to assess c-MET expression levels (negative, weak, strong).
• Correlation of c-MET expression with clinical data, including metastasis and disease course.

Main Results:

• c-MET expression was assessed in 43 MEN1-related NETs (primary and metastatic).
• Strong positive c-MET expression (3/43 tumors) was linked to aggressive clinical courses.
• Negative c-MET expression (34/43 tumors) was predominantly associated with stable disease.

Conclusions:

• c-MET expression patterns in MEN1-NETs correlate with disease behavior.
• Targeted c-MET inhibition may offer a personalized therapeutic strategy for MEN1-NET patients.